Human Hepatitis B Immunoglobulin (HBIG)
Market
Human Hepatitis B Immunoglobulin (HBIG) Market
Scope: Industry Analysis, Market Size, Growth,
Trends Till 2031
Request Sample Report
Human Hepatitis B Immunoglobulin (HBIG) Market Size and Growth
The Human Hepatitis B Immunoglobulin (HBIG) market is experiencing steady growth, driven by increasing hepatitis B cases and rising immunoprophylaxis demand. The market size is estimated to reach approximately $600 million by 2026, with key players focusing on product innovations and strategic partnerships to enhance market presence and accessibility.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Baxter
◍ CSL
◍ Bayer
◍ Grifols
◍ Octapharma
◍ Shanghai RAAS
◍ Hualan Biological
◍ China Biologic
◍ Tiantan Biologic
◍ Shuanglin Bio-pharmacy
◍ Sichuan Yuanda Shuyang
◍ Boya Bio-pharmaceutical
◍ Shanghai Institute of Biological
The Human Hepatitis B Immunoglobulin (HBIG) market features key players like Baxter, CSL, Bayer, Grifols, and Octapharma. These companies enhance market growth through R&D, expanding production capacities, and strategic partnerships. Sales revenues highlight their prominence: Baxter ($12.8B), Grifols ($2.3B), and CSL ($8.4B).
Request Sample Report
Market Segmentation
By Application
◍ Positive Infants Born to Mothers With Hepatitis B Surface Antigen (HBsAg) ◍ Unexpected Crowd of Hepatitis B
Infection
◍ Close Contacts of Patients with Hepatitis
B and Hepatitis B Virus Carriers
By Product
100IU/Bottle Human Hepatitis B
Immunoglobulin
200IU/Bottle Human Hepatitis B
Immunoglobulin
400IU/Bottle Human Hepatitis B
Immunoglobulin
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
